P0883: Proactive pharmacogenomics in azathioprine-treated pediatric inflammatory bowel disease at a Chinese tertiary hospitalECCO'25Year: 2025
Authors: Long, C.(1)*;Huang, Y.(1);
(1)Children's Hospital of Fudan University, Department of Gastroenterology, Shanghai, China;
P0884: Environmental impact and costs of a switching program of intravenous to subcutaneous infliximab in Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Oliveira, R.(1)*;Roseira, J.(1);Araújo, N.(2);Cavaco, C.(1);André, J.(1);Sousa, M.(2);Tavares de Sousa, H.(1);Cunha, M.(3);
(1)Unidade Local de Saúde do Algarve, Gastroenterology Department, Portimão, Portugal;(2)Unidade Local de Saúde do Algarve, Pharmacy Department, Portimão, Portugal;(3)Unidade Local de Saúde do Algarve, Colorectal Group - General Surgery Department, Portimão, Portugal;
P0885: Therapeutic Concepts for Pyoderma Gangrenosum as an Extraintestinal Manifestation in Chronic Inflammatory Bowel DiseasesECCO'25Year: 2025
Authors: Guse, J.(1)*;Rüddel, J.(1);Teich, N.(2);Stallmach, A.(1);Lange, K.(1);
(1)Jena University Hospital, Department of Internal Medicine IV, Jena, Germany;(2)Internal Medicine Practice for Digestive and Metabolic Diseases, Internal Medicine Practice for Digestive and Metabolic Diseases, Leipzig, Germany;
P0886: The association of psychological factors and future exacerbation of Inflammatory activity in Crohn’s Disease: A prospective Cohort StudyECCO'25Year: 2025
Authors: Barda, L.(1,2)*;Talan Asher, A.(1,2);Yablecovitch, D.(1,2);Haj, O.(1,2);Haberman ziv, Y.(1,2);Ungar, B.(1,2);Eliakim, R.(1,2);Kopylov, U.(1,2);Ben-Horin, S.(1,2);
(1)Sheba Medical center, Gastroenterology Department, Ramat Gan, Israel;(2)Tel Aviv University, Faculty of Medical and Health Sciences, Tel Aviv, Israel;
P0887: Through the lens of inflammatory bowel disease: Impact of rheumatological involvement on disease courseECCO'25Year: 2025
Authors: Khemiri, W.(1)*;Ayari, M.(1);Bettaieb, H.(2);Boudokhane, M.(2);Ben Azzouz, S.(1);Douggui , M.H.(1);Jomni, T.(1);
(1)FSI Hospital, Gastroenterology department, La Marsa, Tunisia;(2)FSI Hospital, Rheumatology department, La Marsa, Tunisia;
P0888: Time-trends in the management of postoperative Crohn’s Disease and its impact on long-term surgical recurrence. Data from the ENEIDA registry.ECCO'25Year: 2025
Authors: Piñero, G.S.(1)*;Nos, P.(2);Ricart, E.(3);Calafat, M.(1);Riestra, S.(4);Mesonero, F.(5);Iglesias-Flores, E.(6);Pascual-Moreno, I.(7);Vera, I.(8);Martín-Arranz, M.D.(9);De Castro, L.(10);Taxonera, C.(11);Rivero, M.(12);Guardiola, J.(13);Arranz Hernandez, L.(14);Arias Garcia, L.(15);Varela, P.(16);Giordano, A.(17);Gisbert, J.P.(18);Barrio, J.(19);Calvet, X.(20);Gutiérrez-Casbas, A.(21);García-López, S.(22);Gargallo-Puyuelo, C.J.(23);Huguet, J.M.(24);Moraleja, I.(25);Pérez-Calle, J.L.(26);Bujanda, L.(27);Zabana, Y.(28);Ramos, L.(29);Sierra , M.(30);Carpio, D.(31);Barreiro-de-Acosta, M.(32);Lorente , R.(33);Bermejo, F.(34);González-Lama, Y.(35);Navarro-Llavat, M.(36);Márquez, L.(37);Mañosa, M.(1);Domènech, E.(1);
(1)Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain;(2)Hospital Universitario y Politécnico de la Fe, Gastroenterology, Valencia, Spain;(3)Hospital Clínic de Barcelona, Gastroenterology, Barcelona, Spain;(4)Hospital Universitario Central de Asturias, Gastroenterology, Oviedo, Spain;(5)Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain;(6)Hospital Universitario Reina Sofía, Gastroenterology, Córdoba, Spain;(7)Hospital Clinic Universitari de Valencia, Gastroenterology, Valencia, Spain;(8)Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology, Madrid, Spain;(9)Hospital Álvaro Cunqueiro, Gastroenterology, Vigo, Spain;(10)Hospital Universitario La Paz, Gastroenterology, Madrid, Spain;(11)Hospital Clínico San Carlos, Gastroenterology, Madrid, Spain;(12)Hospital Universitario Marques de Valdecilla, Gastroenterology, Santander, Spain;(13)Hospital Universitari de Bellvitge, Gastroenterology, Barcelona, Spain;(14)Hospital Universitario Nuestra Señora de Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain;(15)Hospital Universitario de Burgos, Gastroenterology, Burgos, Spain;(16)Hospital Universitario de Cabueñes, Gastroenterology, Gijon, Spain;(17)Hospital Universitari de la Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain;(18)Hospital Universitario de la Princesa, Gastroenterology, Madrid, Spain;(19)Hospital Universitario Río Hortega, Gastroenterology, Valladolid, Spain;(20)Consorci Corporació Sanitària Parc Taulí de Sabadell, Gastroenterology, Sabadell, Spain;(21)Hospital General Universitario de Alicante, Gastroenterology, Alicante, Spain;(22)Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain;(23)Hospital Clínico Universitario "Lozano Blesa", Gastroenterology, Zaragoza, Spain;(24)Consorcio Hospital General Universitario de Valencia, Gastroenterology, Valencia, Spain;(25)Hospital Universitario de Galdakao, Gastroenterology, Galdakao, Spain;(26)Hospital Universitario Fundación de Alcorcón, Gastroenterology, Alcorcón, Spain;(27)Hospital Universitario Donostia, Gastroenterology, Donostia, Spain;(28)Hospital Universitari Mutua Terrassa, Gastroenterology, Terrassa, Spain;(29)Hospital Universitario de Canarias, Gastroenterology, Santa Cruz de Tenerife, Spain;(30)Complejo Asistencial Universitario de León, Gastroenterology, León, Spain;(31)Complexo Hospitalario de Pontevedra, Gastroenterology, Pontevedra, Spain;(32)Hospital Clínico Universitario de Santiago, Gastroenterology, Santiago de Compostela, Spain;(33)Hospital General Universitario de Ciudad Real, Gastroenterology, Ciudad Real, Spain;(34)Hospital Universitario de Fuenlabrada, Gastroenterology, Madrid, Spain;(35)Hospital Universitario Doce de Octubre, Gastroenterology, Madrid, Spain;(36)Hospital de Sant Joan Despì Moisès Broggi, Gastroenterology, Barcelona, Spain;(37)Hospital del Mar de Barcelona, Gastroenterology, Barcelona, Spain; on behalf of the ENEIDA project of GETECCU.
P0889: Efficacy and safety of obefazimod for the fourth and sixth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): 2-year interim analysis after dose de-escalation to 25 mgECCO'25Year: 2025
Authors: Danese, S.(1)*;Sands, B.E.(2);Dulai, P.S.(3);Peyrin-Biroulet, L.(4);Dubinsky, M.(5);Tilg, H.(6);Siegmund, B.(7);Hisamatsu, T.(8);Shan, K.(9);Ploncard, P.(10);Jacobstein, D.(11);Cataldi, F.(12);Rabbat, C.(12);Vermeire, S.(13);
(1)IRCCS Ospedale San Raffaele, Gastroenterology and Endoscopy, San Raffaele, Italy;(2)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(3)Feinberg School of Medicine Northwestern University, Gastroenterology and Hepatology, Chicago, United States;(4)INFINY Institute- INSERM NGERE- CHRU Nancy, Department of Gastroenterology, Vandœuvre-lès-Nancy, France;(5)Mount Sinai Kravis Children’s Hospital, Pediatric GI and Nutrition, New York, United States;(6)Medical University Innsbruck, Department of Gastroenterology- Hepatology- Endocrinology & Metabolism, Innsbruck, Austria;(7)Charité – Universitätsmedizin Berlin, Department of Gastroenterology- Infectious Diseases and Rheumatology, Berlin, Germany;(8)Kyorin University School of Medicine, Department of Gastroenterology and Hepatology, Tokyo, Japan;(9)Abivax, Biometrics, Paris, France;(10)Abivax, Clinical Operations, Paris, France;(11)Abivax, Clinical Development, Paris, France;(12)Abivax, Medical Affairs, Paris, France;(13)University hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;
1. Vermeire S, et al. J Crohns Colitis 2023
2. Vermeire S, et al. Gastroenterology 2021
3. Vermeire S, et al. The Lancet Gastroenterol & Hepatol 2022.
P0890: Real-World Outcomes of Upadacitinib in Crohn’s Disease: Insights from ENEIDA database.ECCO'25Year: 2025
Authors: Iborra, M.(1)*;Botella, B.(2);Martín-Arranz, M.D.(3);Ceballos, D.(4);Martínez-Pascual, C.(5);Ripoll, P.(1);Varela, P.(6);Moreta, M.(7);Montserrat, A.(8);González-Lama, Y.(9);Rodríguez-González, E.(10);Vicuña, M.(11);Gisbert, J.P.(12);Ordás, I.(13);Argüelles-Arias, F.(14);Tosca, J.(15);Vicente, R.(16);Sierra, M.(17);Rodríguez-Lago, I.(18);Martín-Rodríguez, D.(19);Paredes, J.M.(20);Sicilia, B.(21);García de la Filia, I.(22);Jiménez, N.(23);Barreiro de Acosta, M.(24);Betoré, E.(25);Ferrer, I.(26);García-Allés, L.(27);Huguet, J.M.(28);Castellet, S.(29);García, M.J.(30);Gutiérrez, A.(31);Ponferrada, Á.(32);Ramos, L.(33);Caldafat, M.(34);Domènech, E.(34);Nos, P.(1);
(1)Hospital Universitario y Politécnico La Fe, Gastroenterology, Valencia, Spain;(2)Hospital Universitario Puerta de Hierro, Gastroenterology, Madrid, Spain;(3)Hospital Universitario La Paz, Gastroenterology, Madrid, Spain;(4)Hospital Universitario de Gran Canaria Dr. Negrín, Gastroenterology, Las Palmas, Spain;(5)Hospital Clínico Universitario Virgen de La Arrixaca, Gastroenterology, Murcia, Spain;(6)Hospital Universitario de Cabueñes, Gastroenterology, Gijón, Spain;(7)Hospital Río Hortega, Gastroenterology, Valladolid, Spain;(8)Hospital Universitario Parc Taulí, Gastroenterology, Barcelona, Spain;(9)Hospital Universitario Doce de Octubre, Gastroenterology, Madrid, Spain;(10)Hospital Nuestra Señora de La Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain;(11)Complejo Hospitalario de Navarra, Gastroenterology, Pamplona, Spain;(12)Hospital Universitario de La Princesa, Gastroenterology, Madrid, Spain;(13)Hospital Clínic, Gastroenterology, Barcelona, Spain;(14)Hospital Universitario Virgen de la Macarena, Gastroenterology, Sevilla, Spain;(15)Hospital Clínico de Valencia, Gastroenterology, Valencia, Spain;(16)Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain;(17)Complejo Asistencial Universitario de León, Gastroenterology, León, Spain;(18)Hospital Galdakao, Gastroenterology, Galdakao, Spain;(19)Hospital Universitario Infanta Cristina, Gastroenterology, Madrid, Spain;(20)Hospital Peset de Valencia, Gastroenterology, Valencia, Spain;(21)Hospital de Burgos, Gastroenterology, Burgos, Spain;(22)Hospital Ramón y Cajal, Gastroenterology, Madrid, Spain;(23)Hospital General Universitario de Elche, Gastroenterology, Elche, Spain;(24)Hospital Universitario de Santiago de Compostela, Gastroenterology, Santiago de Compostela, Spain;(25)Hospital San Jorge, Gastroenterology, Huesca, Spain;(26)Hospital de Manises, Gastroenterology, Valencia, Spain;(27)Hospital Sierrallana, Gastroenterology, Torrelavega, Spain;(28)Hospital General Universitario de Valencia, Gastroenterology, Valencia, Spain;(29)Hospital Universitari de Bellvitge, Gastroenterology, Barcelona, Spain;(30)Hospital Universitario Marqués de Valdecilla, Gastroenterology, Santander, Spain;(31)Hospital General de Alicante, Gastroenterology, Alicante, Spain;(32)Hospital Universitario Infanta Leonor, Gastroenterology, Madrid, Spain;(33)Hospital Universitario de Canarias, Gastroenterology, Santa Cruz de Tenerife, Spain;(34)Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain;
P0891: Efficacy and safety of subcutaneous guselkumab rescue therapy in patients with moderately to severely active Crohn’s disease and inadequate response to ustekinumab: Phase 2 GALAXI 1 study long-term extension resultsECCO'25Year: 2025
Authors: Afzali, A.(1);Wolf, D.(2);Leong, R.(3);Salese, L.(4);Gao, L.L.(4);Busse, C.(4);Panés, J.(5)*;
(1)University of Cincinnati- College of Medicine, Division of Digestive Diseases, Cincinnati, United States;(2)Atlanta Gastroenterology Associates, Gastroenterology, Atlanta, United States;(3)Macquarie University Hospital, Gastroenterology, Sydney, Australia;(4)Janssen Research & Development- LLC, Immunology, Spring House, United States;(5)Hospital Clínic de Barcelona- IDIBAPS- CIBERehd, Gastroenterology, Barcelona, Spain;
P0892: Real-life vs clinical trial access to biological therapy: findings from an Italian-American study on inflammatory bowel diseaseECCO'25Year: 2025
Authors: Di Vincenzo, F.(1)*;Principessa, C.(1);Ioannou, S.(2);Capobianco, I.(1);Gasbarrini, A.(3);Laterza, L.(4);Abreu, M.T.(5);Scaldaferri, F.(6);
(1)Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy;(2)University of Miami - Jackson Health System, Division of Gastroenterology and Hepatology, Miami, United States;(3)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Università Cattolica del Sacro Cuore, UOC Medicina Interna e Gastroenterologia- Digestive Disease Center CeMAD- Dipartimento di Scienze Mediche e Chirurgiche- Dipartimento di Medicina e Chirurgia Traslazionale, Roma, Italy;(4)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Università Cattolica del Sacro Cuore, IBD Unit- Digestive Disease center CeMAD- Department of Medical and Surgical Sciences, Roma, Italy;(5)University of Miami Miller School of Medicine, Division of Gastroenterology- Department of Medicine, Miami, United States;(6)Fondazione Policlinico Universitario "A. Gemelli" IRCCS- Università Cattolica del Sacro Cuore, IBD Unit- CeMAD Translational Research Laboratories- Digestive Disease Center CeMAD- Dipartimento di Scienze Mediche e Chirurgiche- Dipartimento di Medicina e Chirurgia Traslazionale, Rome, Italy;
1. Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A; International Organization for the Study of IBD. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. Epu
P0893: Angiopoietin-like Protein 8 (ANGPTL8) in Inflammatory Bowel Disease and Its Response to Anti-TNFα Therapy; A Prospective Multi Center Study.ECCO'25Year: 2025
Authors: Shehab, M.(1)*;Al-Fajri, S.(2);Alborom, M.(2);Alrashed, F.(3);Alshammaa, F.(2);Alfadhli, A.(2);Devarajan, S.(4);Abu-Farha, M.(4);Alkhairi, I.(4);Cherian, P.(4);Al-Mulla, F.(4);Abubaker, J.(4);
(1)Mubarak Alkabeer University Hospital, Department of Internal Medicine, Kuwait, Kuwait;(2)Mubarak Alkabeer University Hospital, Department of Internal Medicine, Jabriya, Kuwait;(3)Faculty of Pharmacy- Kuwait University, Department of Pharmacy Practice, Jabriya, Kuwait;(4)Dasman Diabetes Institute, Department of Biochemistry and Molecular Biology, Dasman, Kuwait;
P0894: Impact of Mirikizumab on Extraintestinal Manifestations of Crohn’s Disease in the VIVID-1 StudyECCO'25Year: 2025
Authors: Vavricka, S.R.(1)*;Ananthakrishnan, A.(2);Long, M.(3);Melmed , G.(4);Narula , N.(5);Rubin , D.(6);Hon, E.(7);Carlier, H.(7);Moses, R.(7);Yu , G.(7);Zang, H.(7);Kucharzik, T.(8);
(1)Triemli Hospital, Gastroenterology and Hepatology, Zurich, Switzerland;(2)Harvard Medical School, Gastroenterology, Boston, United States;(3)University of North Carolina School of Medicine, Gastroenterology and Hepatology, Chapel Hill, United States;(4)Cedars Sinai, Gastroenterology, Los Angeles, United States;(5)McMaster University, Health Sciences, Ontario, Canada;(6)University of Chicago Medicine, Medicine, Chicago, United States;(7)Eli Lilly and Company, Lilly Immunology, Indianapolis, United States;(8)Municipal Hospital of Lüneburg, Department of Internal Medicine and Gastroenterology, Lüneburg, Germany;
1. Ferrante, et al., (in press, 2024) Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn’s disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study
P0895: The Prognostic Significance of Visceral Adiposity indices in conjunction with Plasma Trace Elements in Newly Diagnosed Crohn's DiseaseECCO'25Year: 2025
Authors: Luo, J.(1);Li, G.(1);Hu, W.(2);Shen, K.(3);Huang, X.(4);Xu, D.(1);Wang, X.(1);Ma, Y.(1);lv, M.(1);Li, S.(1);Chen, Y.(1);Yu, Q.(1)*;
(1)the Second Affiliated Hospital Zhejiang University School of Medicine, IBD centre- Department of gastroenterology, Hangzhou, China;(2)The First Affiliated Hospital of Zhejiang Chinese Medical University Zhejiang Provincial Hospital of Chinese Medicine, IBD centre- Department of gastroenterology, Hangzhou, China;(3)the Second Affiliated Hospital Zhejiang University School of Medicine, IBD centre- Department of radiology, Hangzou, China;(4)the Second Affiliated Hospital Zhejiang University School of Medicine, IBD centre- Department of nutrition, Hangzhou, China;
P0896: A double-blind, randomized, placebo-controlled, single-center, pilot study evaluating the efficacy of a synbiotic formulation in modulating gut microbiota biodiversity in patients with mild-to-moderate UC in clinical and endoscopic remissionECCO'25Year: 2025
Authors: Murgiano, M.(1)*;Bartocci, B.(1);Del Gaudio, A.(1);Rozera, T.(1);Puca, P.(1);Parisio, L.(1);Mignini, I.(1);Coppola, G.(1);De Biasio, F.(1);Lavigna, D.I.R.(1);Laterza, L.(1);Pugliese, D.(1);Papa, A.(1);Gasbarrini, A.(1);Scaldaferri, F.(1);Lopetuso, L.R.(1,2);
(1)Medicina Interna e Gastroenterologia- CEMAD Centro Malattie dell'Apparato Digerente- Università Cattolica del Sacro Cuore- Fondazione Policlinico Gemelli IRCCS- Roma- Italia, Dipartimento di Scienze Mediche e Chirurgiche, Roma, Italy;(2)Università di Chieti-Pescara- Chieti- Italia, Dipartimento di Medicina e Scienze dell'Invecchiamento- Gabriele d'Annunzio-, Chieti, Italy;
P0897: Association of HLA Genotypes with Anti-Drug Antibody Development in Taiwanese Inflammatory Bowel Disease Patients Undergoing Biologic TherapiesECCO'25Year: 2025
Authors: Weng, M.T.(1)*;Yao , C.Y.(2);Lin, W.C.(3);Lai, S.K.(4);Chen, P.L.(5);Tung, C.C.(6);Wong, J.M.(7);Wei, S.C.(7);
(1)National Taiwan University Hospital- Hsin-Chu Branch, Department of Medical Research, Hsin-Chu, Taiwan;(2)National Taiwan University Hospital, Department of Laboratory Medicine, Taipei, Taiwan;(3)MacKay Memorial Hospital, Department of Internal Medicine, Taipei, Taiwan;(4)Academia Sinica and National Taiwan University, Academia Sinica and National Taiwan University, Taipei, Taiwan;(5)National Taiwan University Hospital, Departments of Internal Medicine, Taipei, Taiwan;(6)National Taiwan University Hospital, Department of Integrated Diagnostic & Therapeutic, Taipei, Taiwan;(7)National Taiwan University Hospital, Department of Internal Medicine, Taipei, Taiwan;
1. Sazonovs A, Kennedy NA, Moutsianas L, et al. HLA-DQA1*05 Carriage Associated WithDevelopment of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients WithCrohn's Disease. Gastroenterology 2020;158:189-199.
P0898: Comparative Study on the Efficacy of Biologics with Dietary Intervention in Crohn's Disease: Evaluating the Impact of Crohn's Disease Exclusion Diet and partial Entral nutrition Combination with BiologicsECCO'25Year: 2025
Authors: Kim, H.S.(1)*;Kim, D.H.(2);Lim, J.W.(1);Kim, D.S.(1);
(1)Chonnam National University Hospital and Medical School, Division of Gastroenterology- Department of Internal Medicine, Gwangju, Korea- Republic Of;(2)Chonnam National University Hospital, Division of gastroenterology- Department of Internal medicine and Inflammatory Bowel disease Clinic, Gwnagju, Korea- Republic Of;
1. Chen J, Wellens J, Kalla R, et al. Intake of Ultra-processed Foods Is Associated with an Increased Risk of Crohn's Disease: A Cross-sectional and Prospective Analysis of 187 154 Participants in the UK Biobank. J Crohns Colitis 2023;17(4):535-552. (In eng). DOI: 10.1093/ecco-jcc/jjac167.
2. Narula N, Chang NH, Mohammad D, et al. Food Processing and Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 2023;21(10):2483-2495.e1. (In eng). DOI: 10.1016/j.cgh.2023.01.012.
3. Allin KH, Ungaro RC, Agrawal M. Ultraprocessed Foods and the Risk of Inflammatory Bowel Disease: Is it Time to Modify Diet? Gastroenterology 2022;162(2):652-654. (In eng). DOI: 10.1053/j.gastro.2021.09.053.
4. Narula N, Wong ECL, Dehghan M, et al. Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study. Bmj 2021;374:n1554. (In eng). DOI: 10.1136/bmj.n1554.
5. Kuenzig ME, Fung SG, Marderfeld L, et al. Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review. Gastroenterology 2022;162(4):1147-1159.e4. (In eng). DOI: 10.1053/j.gastro.2021.12.282.
6. Levine A, Sigall Boneh R, Wine E. Evolving role of diet in the pathogenesis and treatment of inflammatory bowel diseases. Gut 2018;67(9):1726-1738. (In eng). DOI: 10.1136/gutjnl-2017-315866.
7. Chassaing B, Compher C, Bonhomme B, et al. Randomized Controlled-Feeding Study of Dietary Emulsifier Carboxymethylcellulose Reveals Detrimental Impacts on the Gut Microbiota and Metabolome. Gastroenterology 2022;162(3):743-756. (In eng). DOI: 10.1053/j.gastro.2021.11.006.
8. Schwärzler J, Mayr L, Vich Vila A, et al. PUFA-Induced Metabolic Enteritis as a Fuel for Crohn's Disease. Gastroenterology 2022;162(6):1690-1704. (In eng). DOI: 10.1053/j.gastro.2022.01.004.
9. Armstrong HK, Bording-Jorgensen M, Santer DM, et al. Unfermented β-fructan Fibers Fuel Inflammation in Select Inflammatory Bowel Disease Patients. Gastroenterology 2023;164(2):228-240. (In eng). DOI: 10.1053/j.gastro.2022.09.034.
10. Ghiboub M, Penny S, Verburgt CM, et al. Metabolome Changes With Diet-Induced Remission in Pediatric Crohn's Disease. Gastroenterology 2022;163(4):922-936.e15. (In eng). DOI: 10.1053/j.gastro.2022.05.050.
P0899: Previous extended colectomy is associated with particularly high risk of postoperative small bowel fistula in Crohn’s disease patientsECCO'25Year: 2025
Authors: Iesalnieks, I.(1)*;Bercher, M.(2);Schmitz, A.(2);
(1)Evangelisches Krankenhaus Kalk, Department of surgery, Cologne, Germany;(2)Evangelisches Krankenhaus Kalk, Surgery, Cologne, Germany;
P0900: Hyperbaric oxygen therapy downstages refractory perianal fistulizing Crohn’s disease and allows for surgical closureECCO'25Year: 2025
Authors: Mulders, L.(1)*;Beek, K.(2);Becker, M.(3,4);Koelink, P.(4);Zwart, M.(1);van der Bilt, J.(5);Vlug, M.(3);Tielbeek, J.(6);Rietdijk, S.(7);Jansen, J.(7);Ridderikhof, M.(8,9);de Jonge, W.(4);Bemelman, W.(3);Stoker, J.(2);D'Haens, G.(1);van Hulst, R.(8,10);Wildenberg, M.(4);Buskens, C.(3);Gecse, K.(1);
(1)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(2)Amsterdam UMC, Department of Radiology and Nuclear Medicine, Amsterdam, The Netherlands;(3)Amsterdam UMC, Department of Surgery, Amsterdam, The Netherlands;(4)Amsterdam UMC, Tytgat Institute for Liver and Intestinal Research, Amsterdam, The Netherlands;(5)Flevoziekenhuis, Department of Surgery, Amsterdam, The Netherlands;(6)Spaarne Gasthuis, Department of Radiology and Nuclear Medicine, Haarlem, The Netherlands;(7)OLVG, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(8)Amsterdam UMC, Department of Hyperbaric Medicine, Amsterdam, The Netherlands;(9)Amsterdam UMC, Department of Emergency Medicine, Amsterdam, The Netherlands;(10)Amsterdam UMC, Department of Anesthesiology, Amsterdam, The Netherlands; AMFIBIO study group
P0901: Infliximab chronotherapy: timing of intravenous infliximab administration affects inflammatory markers and clinical outcomes in inflammatory bowel diseaseECCO'25Year: 2025
Authors: Post, Z.(1)*;Maniak, A.(1);DeMeo, A.(2);Keshavarzian, A.(1);
(1)Rush University Medical Center, Digestive Diseases and Nutrition, Chicago, United States;(2)Rush Medical College, Medical School, Chicago, United States;
1. Scheiermann C, Gibbs J, Ince L, Loudon A. Clocking in to immunity. Nat Rev Immunol. 2018;18(7):423-437. doi:10.1038/s41577-018-0008-4
2. Petrovsky N, Harrison LC. The chronobiology of human cytokine production. Int Rev Immunol. 1998;16(5-6):635-649. doi:10.3109/08830189809043012
P0902: Development and validation of a novel model based on clinical characteristic variables to predict disease behavior progression in patients with stricturing Crohn's diseaseECCO'25Year: 2025
Authors: Wang, Y.(1)*;Chen, X.(2);Liu, Z.(1);Gu, Y.(3);Mao, R.(1);
(1)The First Affiliated Hospital- Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China;(2)Sun Yat-sen University, Zhongshan School of Medicine, Guangzhou, China;(3)Ruijin Hospital- Shanghai Jiao Tong University School of Medicine, Department of Gastroenterology, Shanghai, China;